VERIFIEDET Stocks·18 Aug 2026neutral

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

AI Summary

·Lupin received USFDA approval for generic Pitolisant Tablets.
·The approval strengthens Lupin's US portfolio and specialty generics presence.
·The stock trades below most key moving averages, indicating subdued near-term momentum.